Georgia's Online Cancer Information Center

Find A Clinical Trial

Phase 1b/2 Study of Carfilzomib in Combination With Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (UK R3 Induction Backbone) in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Status
Active
Cancer Type
Acute Lymphoblastic Leukemia
Trial Phase
Phase I
Phase II
Eligibility
18 and under, Male and Female
Study Type
Biomarker/Laboratory analysis
Treatment
NCD ID
NCT02303821
Protocol IDs
CFZ008 (primary)
NCI-2014-02601
2014-001633-84
Study Sponsor
Onyx Therapeutics, Inc.

Summary

The purpose of the study is to determine the maximum tolerated dose and assess the safety,

tolerability and activity of carfilzomib, alone and in combination with induction

chemotherapy, in children with relapsed or refractory acute lymphoblastic leukemia (ALL).

Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.